Search - tctmd.com

Displaying 521 - 540 of 692

Sort: Relevancy | Date

Presentation TCT 2016

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

Presenter: Emerson C. Perin, Bernard J. Gersh

October 31, 2016

Presentation TCT 2016

What Are the Right Endpoints for CLI Clinical Trials?

Presenter: George L Adams, John F Angle, Patrick J. Geraghty

October 31, 2016

Presentation TCT 2016

Cells Alone Work: Lessons From Recent Clinical Trials

Presenter: Emerson C. Perin

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

Presenter: Antonio L. Bartorelli, Kenneth Chin, Ariel Furer

October 31, 2016

Presentation TCT 2016

TCT 67: Impact of the SYNTAX Score in Patients With Diabetes and Left-Main and/or Multivessel Coronary Disease: A Pooled Analysis of Individual Patient Level Data From the SYNTAX, PRECOMBAT and BEST Trials

Presenter: Sorin J. Brener, Jean-François Tanguay, Rafael Cavalcante

October 31, 2016

Presentation TCT 2016

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

Presenter: Sorin J. Brener, Jean-François Tanguay, Jaya Chandrasekhar

October 31, 2016

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Presenter: Eugene H. Blackstone, Robert W. Yeh, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Presenter: Eugene H. Blackstone, Robert W. Yeh, Tracy Y. Wang

October 30, 2016

Presentation TCT 2016

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Martin B. Leon

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Presenter: Eugene H. Blackstone, Robert W. Yeh, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Advertisement

Improving Clinical Science: Priorities and Methods of Clinical Trials in Cardiovascular Regenerative Medicine

What Are the Right Endpoints for CLI Clinical Trials?

Cells Alone Work: Lessons From Recent Clinical Trials

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

TCT 67: Impact of the SYNTAX Score in Patients With Diabetes and Left-Main and/or Multivessel Coronary Disease: A Pooled Analysis of Individual Patient Level Data From the SYNTAX, PRECOMBAT and BEST Trials

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

FDA Perspectives

Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content